Lung Cancer Clinical Trial
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
Patients must have advanced or metastatic NSCLC or cutaneous melanoma
Presence of KRAS or BRAF mutation (NSCLC) or NRAS mutation (cutaneous melanoma) in tumor tissue
All patients participating in this clinical trial must have progressed following standard therapy or, in the opinion of the Investigator, no effective standard therapy exists, is tolerated, appropriate or is considered equivalent to study treatment.
ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
-Dose expansion - KRAS or NRAS mutant patients groups: Prior treatment with a RAFi (including any BRAFi and pan-RAFi), MEKi and/or ERKi. (Patients with KRAS mutant NSCLC with prior G12C inhibitor treatments are also excluded in the LXH254+trametinib expansion part). BRAF mutant patients group: Prior treatment with any EGFR, ALK, ROS1, KRAS, RAF (both BRAFV600 selective and pan-RAF), MEK1/2 and/or ERK1/2 inhibitors (for patients with BRAF V600 mutant NSCLC, prior treatments with BRAF and MEK1/2 inhibitors are allowed).
Patients who have received more than 3 lines of anti-cancer therapy are excluded.
History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.
Patients with Gilbert's syndrome or other heritable diseases of bile processing.
Other protocol-defined inclusion/exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 31 Locations for this study
San Diego California, 92103, United States
San Francisco California, 94143, United States
Boston Massachusetts, 02114, United States
New York New York, 10065, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
Westmead New South Wales, 2145, Australia
Melbourne Victoria, 3000, Australia
Leuven , 3000, Belgium
Lyon Cedex , 69373, France
Paris Cedex 10 , 75475, France
Villejuif Cedex , 94800, France
Dresden , 01307, Germany
Essen , 45147, Germany
Frankfurt , 60590, Germany
Koeln , 50937, Germany
Tel Aviv , 64239, Israel
Milano MI, 20133, Italy
Milano MI, 20162, Italy
Rozzano MI, 20089, Italy
Verona VR, 37126, Italy
Napoli , 80131, Italy
Seoul , 03080, Korea, Republic of
Seoul , 06351, Korea, Republic of
Warszawa , 02 78, Poland
Sevilla Andalucia, 41013, Spain
Barcelona Catalunya, 08035, Spain
Barcelona Catalunya, 08036, Spain
Valencia Comunidad Valenciana, 46010, Spain
Pamplona Navarra, 31008, Spain
Madrid , 28034, Spain
Stockholm , 171 7, Sweden
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.